Viatris Inc VTRS, previously known as Mylan, has agreed to pay $264 million to resolve a class-action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment.
The proposed settlement would resolve litigation following public outrage in 2016 over Mylan's decision to raise the list price for a pair of EpiPen to $600 from $100 in 2008.
The case until recently was slated to go on trial this month, with the plaintiffs seeking $1 billion in damages, a sum that could be multiplied under some state antitrust laws.
The lawsuit accused Mylan and Pfizer Inc PFE, which manufactured the EpiPen, of engaging in wide-ranging anticompetitive conduct.
Related: India-based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal.
Last year, the U.S. District Judge Daniel Crabtree in Kansas City dismissed much of the case against Mylan, leaving only a claim concerning a 2012 patent litigation settlement with Teva Pharmaceutical Industries Ltd TEVA.
The plaintiffs had alleged the defendants entered into an unlawful "pay-for-delay" settlement with Teva that resulted in the delayed release of a generic version of the EpiPen.
Price Action: VTRS shares are down 23.5% at $11.12 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
